Inclisiran and the ORION clinical development programmeEvolution of PCSK9 inhibitors: Pipedream or Evidence based RealityHow do we recognize FH in clinical practice?PCSK9 Inhibitors: A View of Clinical StudiesFH in children and adolescentsView all slides »
ESC 2021 Inclisiran in polyvascular disease
Huygens: Does PCSK9 inhibition impact the vulnerable plaque?
LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Why should clinical practice move to an intensive LDL-C lowering approach?View all videos »